The FDA approval of an in-house RFFIT lab is a modest positive for Kamada's rabies franchise, potentially improving margins and reducing supply chain risk. Monitor for any future guidance updates or margin improvements in upcoming quarterly reports.
KMDA drugs
KMDA drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 1 $7.70entry
- T+1 · 6mo ago −2.47%α −2.61% · $7.51
- T+5 · 5mo ago −6.88%α −4.13% · $7.17
- T+20 · 5mo ago −4.68%α −3.38% · $7.34
- T+60 · 3mo ago +12.08%α +10.85% · $8.63
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kamada announced FDA approval of its new in-house RFFIT laboratory for rabies potency testing, which supports the manufacturing of KEDRAB and KAMRAB. The lab is expected to improve operational efficiencies and reduce reliance on external testing for its leading rabies franchise, which generated over $70 million in 2025 sales.
Key Facts
- FDA approved Kamada's new in-house RFFIT laboratory for rabies virus neutralization testing.
- The lab is located at Kamada's Beit Kama, Israel plant and is one of a limited number worldwide capable of such tests.
- The lab was also approved by Health Canada and the Israeli Ministry of Health prior to FDA approval.
- In 2025, Kamada's sales of KEDRAB and KAMRAB totaled over $70 million.
- The lab supports manufacturing of KEDRAB and KAMRAB from plasma collection to final product release.
Financial Impact
Operational efficiency gains on a franchise generating over $70 million in annual sales; no specific cost savings or revenue impact quantified.
Risk Factors
- No quantified financial impact from the lab approval; benefits may be gradual.
- Operational execution risk in transitioning testing from external to in-house capabilities.
- Geopolitical risk from the lab's location in Israel.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-063140 |
| Document: ea0292886-6k_kamada.htm | 0001213900-26-063140 |
| Document: 0001213900-26-063140-index-headers.html | 0001213900-26-063140 |
| Document: 0001213900-26-063140-index.html | 0001213900-26-063140 |
| Document: 0001213900-26-063140.txt | 0001213900-26-063140 |
Track record
25 reports on KMDA
8 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +16.13% at T+20 after the Aug 12, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 9, 20267d ago 6-K Bullish 6/10 No price data
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $7.71 to $8.11 Now $8.11 +5.19% ▲ +5.19% +6.88% vs SPY
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $7.36 to $7.71 Now $8.11 +10.19% ▲ +4.76% +4.68% vs SPY
- Oct 6, 20265w ago 6-K Neutral 4/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Oct 6, 20265w ago Press Release Bullish 6/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Oct 5, 20266w ago 6-K Neutral 2/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Sep 17, 20268w ago 6-K Bullish 6/10 Entry $8.67 to $8.83 Now $8.11 −6.46% ▲ +1.85% +1.24% vs SPY
- Sep 16, 20268w ago EFFECT Neutral 3/10 Entry $8.19 to $8.77 Now $8.11 −0.98% ▲ +7.08% +4.52% vs SPY
- Sep 10, 20269w ago 6-K Neutral 2/10 Entry $7.99 to $8.67 Now $8.11 +1.50% ▲ +8.51% +9.01% vs SPY
- Sep 3, 202610w ago Press Release Neutral 2/10 Entry $8.54 to $8.31 Now $8.11 −5.04% ▼ −2.69% −1.48% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers